Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, ...
BTK inhibitors increase infection risk in B-cell lymphoma patients, necessitating proactive monitoring and prophylactic strategies. BTK inhibition affects immune functions, impairing pathogen ...
Targeting BTK has profoundly changed the face of CLL treatment over the past decade. Iterative advances in the cat and mouse game of resistance and redesign have moved BTK inhibitors from covalent to ...
Pirtobrutinib was provided by Loxo Oncology (Stamford, CT). Ibrutinib was purchased from Selleck Chemicals (Houston, TX). Stock solutions of both drugs were made in DMSO. Time-matched, DMSO-treated, ...
Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have disclosed proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked ...
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib ...
• BTK inhibitors are a type of targeted therapy for mantle cell lymphoma that works by blocking a specific enzyme, BTK, which is crucial for the cancer cells’ survival and spread. This interference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results